Newly issued patent in China covers use of antibody cocktails in combination with a microchannel to capture rare cells such as circulating tumor cells (CTCs) from any biological sample of interest SAN DIEGO , May 28, 2019 /PRNewswire/ -- Biocept, Inc .
Further expands global patent estate for capturing and detecting biological targets of interest including rare cells such as circulating tumor cells (CTCs) SAN DIEGO , Aug. 2, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to
Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids
Company further expands its global patent estate for capturing and detecting rare cells of interest, including CTCs, to aid the treatment of patients with cancer SAN DIEGO , June 30, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies
Biocept further expands its patent estate for capturing and detecting target cells of interest, including CTCs SAN DIEGO , Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians
New patent provides broad coverage for the use of antibodies to capture targets of interest, including circulating tumor cells (CTCs) and other materials shed by solid tumors into the blood stream
Biocept Awarded Accreditation by the College of American Pathologists Biocept, Inc. (“Biocept”), an emerging leader in biotechnology, announced today their CLIA laboratory has been awarded accreditation by the Commission on Laboratory Accreditation of the College of American Pathologists (CAP),
SAN DIEGO , July 27, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the appointment of Timothy C. Kennedy as Chief Financial Officer and Senior Vice President
Diagnostic industry veteran plans immediate start SAN DIEGO , Oct. 21, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services, announces the appointment of Samuel D. Riccitelli to its Board of Directors, effective immediately.
SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W.
